D. Boral Capital Reiterates Buy Rating for Context Therapeutics (NASDAQ:CNTX)

D. Boral Capital reiterated their buy rating on shares of Context Therapeutics (NASDAQ:CNTX) in a research report released on Wednesday morning,Benzinga reports. The firm currently has a $9.00 target price on the stock.

A number of other equities analysts have also commented on CNTX. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Context Therapeutics in a report on Friday, March 21st. Citizens Jmp upgraded Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. Finally, JMP Securities began coverage on shares of Context Therapeutics in a research report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $6.17.

Context Therapeutics Trading Up 1.9 %

Shares of NASDAQ:CNTX traded up $0.01 during midday trading on Wednesday, reaching $0.68. The company had a trading volume of 73,137 shares, compared to its average volume of 403,049. The stock has a market cap of $61.27 million, a P/E ratio of -0.75 and a beta of 2.18. The company’s 50 day moving average price is $0.77 and its 200 day moving average price is $1.29. Context Therapeutics has a 52-week low of $0.55 and a 52-week high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. Research analysts forecast that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. State Street Corp increased its position in Context Therapeutics by 21.5% during the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after purchasing an additional 19,800 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Context Therapeutics during the 3rd quarter valued at about $89,000. Franklin Resources Inc. bought a new position in Context Therapeutics in the third quarter worth about $3,689,000. Clear Harbor Asset Management LLC lifted its holdings in Context Therapeutics by 60.6% in the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after buying an additional 21,804 shares during the period. Finally, Geode Capital Management LLC boosted its position in Context Therapeutics by 9.2% during the 4th quarter. Geode Capital Management LLC now owns 628,729 shares of the company’s stock valued at $661,000 after acquiring an additional 52,830 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.